
Indifferent Diagnosis- The Health of BioPharma in 2025
By Frank F. DolanLength2h 35m
About this audiobook
Indifferent Diagnosis: The Health of BioPharma in 2025 is your inside pass to an industry running at two speeds—record-breaking M&A on one end, widespread cash-burn triage on the other. Veteran strategist Frank Dolan unpacks why 40 % of public biotechs are months from insolvency while giants like Pfizer and Novartis spend billions on de-risked assets; how AI, CRISPR, and next-gen delivery tech are redrawing drug-discovery maps; and where regulatory, demographic, and private-equity cross-currents will push the market next. Packed with hard data, boardroom stories, and survival playbooks, this audiobook arms executives, investors, and scientists with the context—and contrarian edge—needed to navigate 2025’s most volatile sector.
Audiobook details
Rating★★★★★ 5.0 (3)
GenreBusiness and Economics
Length2 hrs 35 mins
Narrated byListen with 1,000+ voices
FormateBook with Audio
Publish dateJun 25, 2025
LanguageEnglish
Table of contents
1Introduction
12Chapter 11: Therapeutic Focus Areas in 2025
2Chapter 1: The State of Biopharma in 2025
13Chapter 12: The Role of Technology in Driving Innovation
3Chapter 2: M&A Activity: A Boon and a Burden
14Chapter 13: Regional Trends and Cross-Border Activities
4Chapter 3: Understanding Financial Distress in Biotech Companies
15Chapter 14: Understanding Risk Factors and Managing Market Volatility
5Chapter 4: The IPO Market: Is the Opportunity Shrinking?
16Chapter 15: The Future of Drug Development and Innovation
Show all chaptersShow less
6Chapter 5: Exploring Alternative Financing Strategies
17Chapter 16: The Impact of Demographic Changes on the Market
7Chapter 6: The Rise of Private Equity in the Biopharmaceutical Industry
18Chapter 17: Understanding the Competitive Landscape
8Chapter 7: Long-Term Growth Drivers: Key Factors Shaping Future Success
19Chapter 18: The Evolution of Business Models
9Chapter 8: Regulatory Challenges and Their Impact on the Industry
20Chapter 19: Lessons from 2025: Insights and Predictions for the Future
10Chapter 9: Investor Sentiment – Navigating Cautious Optimism
21Preparing for Future Market Changes
11Chapter 10: Building Strategic Partnerships and Collaborations